345.73

+1.31%↑

CAT

752.55

+1.32%↑

RTX

212.11

+5.09%↑

GEV.US

880

+0.82%↑

229.4

+0.9%↑

345.73

+1.31%↑

CAT

752.55

+1.32%↑

RTX

212.11

+5.09%↑

GEV.US

880

+0.82%↑

229.4

+0.9%↑

345.73

+1.31%↑

CAT

752.55

+1.32%↑

RTX

212.11

+5.09%↑

GEV.US

880

+0.82%↑

229.4

+0.9%↑

345.73

+1.31%↑

CAT

752.55

+1.32%↑

RTX

212.11

+5.09%↑

GEV.US

880

+0.82%↑

229.4

+0.9%↑

345.73

+1.31%↑

CAT

752.55

+1.32%↑

RTX

212.11

+5.09%↑

GEV.US

880

+0.82%↑

229.4

+0.9%↑

Начало・Списък с акции・Ocugen Inc

Ocugen Inc

Затворен

1.93 6.63

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

1.67

Максимум

1.95

Ключови измерители
By Trading Economics
Приходи	-5.3M -20M
Продажби	379K 1.8M
Марж на печалбата	-1,144.463
Служители	95
EBITDA	-4.9M -18M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+321.43% upside

Дивиденти
By Dow Jones
Следващи печалби	4.03.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	56M 537M
Предишно отваряне	-4.7
Предишно затваряне	1.93

Техническа оценка

By Trading Central

Увереност

Strong Bearish Evidence

0.6818 / 0.74 Подкрепа & съпротива

Ocugen Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

2.03.2026 г., 23:41 ч. UTC

Пазарно говорене

Значими събития в новините

Nikkei May Decline on Concerns About Energy Prices -- Market Talk

2.03.2026 г., 23:37 ч. UTC

Пазарно говорене

Значими събития в новините

Gold Edges Higher Amid Middle East Conflict -- Market Talk

2.03.2026 г., 23:26 ч. UTC

Значими събития в новините

How the Iran Conflict Could Pressure Consumer Staples Companies -- Barrons.com

2.03.2026 г., 22:41 ч. UTC

Пазарно говорене

Australian Reits Wait on Recovery in Trading Multiples -- Market Talk

2.03.2026 г., 22:32 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

2.03.2026 г., 22:32 ч. UTC

Пазарно говорене

RBA Cautious About Potential for Energy Supply Shocks -- Market Talk

2.03.2026 г., 22:21 ч. UTC

Пазарно говорене

Port of Tauranga's Upgraded Profit View Still Looks Conservative -- Market Talk

2.03.2026 г., 22:11 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

2.03.2026 г., 22:11 ч. UTC

Пазарно говорене

Don't Lose Sight of Bigger Picture With Summerset -- Market Talk

2.03.2026 г., 22:10 ч. UTC

Придобивния, сливания и поглъщания

IAC Is Near Deal to Sell Care.com to Private-Equity Firm -- WSJ

2.03.2026 г., 22:06 ч. UTC

Пазарно говорене

Channel Infrastructure's Dividend Positively Surprises -- Market Talk

2.03.2026 г., 22:00 ч. UTC

Пазарно говорене

Печалби

Global Forex and Fixed Income Roundup: Market Talk

2.03.2026 г., 22:00 ч. UTC

Пазарно говорене

Печалби

Fashion Retailer Hallenstein Glasson Still a Smart Buy -- Market Talk

2.03.2026 г., 21:50 ч. UTC

Пазарно говорене

Значими събития в новините

Energy & Utilities Roundup: Market Talk

2.03.2026 г., 21:50 ч. UTC

Пазарно говорене

Значими събития в новините

Basic Materials Roundup: Market Talk

2.03.2026 г., 21:50 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

2.03.2026 г., 21:35 ч. UTC

Придобивния, сливания и поглъщания

AT&T Expects Net Debt-To-Adjusted Ebitda Ratio Will Rise to About 3.2x Following Deal With EchoStar and Decline to About 3x by End of 2026

2.03.2026 г., 21:34 ч. UTC

Придобивния, сливания и поглъщания

AT&T Remains on Track to Achieve Its 2026 and Multi-Yr Fincl Guidance

2.03.2026 г., 21:30 ч. UTC

Придобивния, сливания и поглъщания

Update: AES to Be Taken Private in $33 Billion Deal. Why It's the S&P 500's Worst Stock Today. -- Barrons.com

2.03.2026 г., 21:17 ч. UTC

Значими събития в новините

Bank, Brokerage Stocks Recover Lost Ground After Last Week's Selloff -- Despite Iran Conflict -- Barrons.com

2.03.2026 г., 20:44 ч. UTC

Печалби

Berkshire Stock Falls 5% as Earnings, Abel Letter Fail to Excite Investors -- Barrons.com

2.03.2026 г., 20:43 ч. UTC

Пазарно говорене

Значими събития в новините

Treasury Yields Fall, Dollar Strengthens After Attack on Iran -- Market Talk

2.03.2026 г., 20:28 ч. UTC

Печалби

Strategy Stock Rises. The World's Largest Bitcoin Holder Doubles Down on Its Crypto Bet. -- Barrons.com

2.03.2026 г., 20:25 ч. UTC

Пазарно говорене

Значими събития в новините

U.S. Natural Gas Futures Post Moderate Gains -- Market Talk

2.03.2026 г., 20:24 ч. UTC

Печалби

Berkshire Stock Falls 5% as Earnings, Abel Letter Fail to Excite Investors -- Barrons.com

2.03.2026 г., 20:14 ч. UTC

Придобивния, сливания и поглъщания

Update: AES to Be Taken Private in $33 Billion Deal. Why It's the S&P 500's Worst Stock Today. -- Barrons.com

2.03.2026 г., 20:12 ч. UTC

Значими събития в новините

Palantir Rises on Mideast Conflict. Why It's Moving Like a Defense Stock. -- Barrons.com

2.03.2026 г., 20:08 ч. UTC

Пазарно говорене

Значими събития в новините

Global Forex and Fixed Income Roundup: Market Talk

2.03.2026 г., 20:08 ч. UTC

Пазарно говорене

Значими събития в новините

Higher Oil Prices Could Boost Capex in Canada Energy Patch -- Market Talk

2.03.2026 г., 20:05 ч. UTC

Пазарно говорене

Значими събития в новините

Oil Rises On U.S.-Middle East Conflict, But Settles Off Highs -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Ocugen Inc Прогноза

Ценова цел

By TipRanks

321.43% нагоре

12-месечна прогноза

Среден 7.67 USD 321.43%

Висок 8 USD

Нисък 7 USD

Според 3 анализатори от Wall Street, предложили 12-месечна ценова цел за Ocugen Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

3 ratings

Купи

Задържане

Продай

Според 3 анализатори, дали борсови рейтинги на Ocugen Inc през последните 3 месеца.

Техническа оценка

By Trading Central

0.6818 / 0.74Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

There are no events.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Ocugen Inc

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.